The FDA approved a supplemental application for the recombinant human papillomavirus (HPV) 9-valent vaccine (Gardasil 9, Merck) expanding the approved use of the vaccine to include women and men aged 27 through 45 years. This vaccine prevents certain cancers and diseases caused by the nine HPV types covered by the vaccine.
The FDA approved a supplemental application for the recombinant HPV 9–valent vaccine (Gardasil 9, Merck), expanding the approved use of the vaccine to include women and